The GLP-1 Pipeline.
Every next-generation weight-loss drug in development — mechanism, trial stage, and expected FDA timing. Updated weekly.
| Drug | Developer | Mechanism | Form | Phase | Expected FDA | Headline result |
|---|---|---|---|---|---|---|
| Retatrutide | Eli Lilly | Triple agonist (GLP-1 / GIP / glucagon) | Injection | Phase 3 | 2026–2027 | ~24% weight loss at 48 weeks in Phase 2 |
| Orforglipron | Eli Lilly | Oral GLP-1 small molecule | Pill | Phase 3 | 2026 | ~14.7% weight loss at 72 weeks (ATTAIN-1) |
| CagriSema | Novo Nordisk | Amylin (cagrilintide) + semaglutide | Injection | Phase 3 | 2026 | ~22% weight loss at 68 weeks (REDEFINE-1) |
| MariTide | Amgen | GLP-1 + GIP antagonist, monthly injection | Injection | Phase 3 | 2027 | ~20% weight loss at 52 weeks (Phase 2) |
| Survodutide | Boehringer / Zealand | Dual GLP-1 / glucagon agonist | Injection | Phase 3 | 2027 | ~19% weight loss at 46 weeks |
Why this matters
The GLP-1 class is still early. Today's leaders (Wegovy, Zepbound) will be followed within 12–24 months by drugs that are meaningfully more effective, easier to take, or dramatically cheaper. If you're starting treatment now, knowing what's coming helps you plan.
Want pipeline updates when they break? Subscribe to The Sherpa Weekly.